Dr. Barbara Pro is a clinician, researcher, and professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, in the Division of Hematology and Oncology. As clinical director of the lymphoma program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia, Dr. Pro leads a multi-disciplinary team of lymphoma experts dedicated to translating discoveries in the lab into new and better treatments for patients.
Dr. Pro’s research and clinical practice focuses on T-cell lymphoma, a rare form of non-Hodgkin lymphoma. Widely recognized for her expertise in drug development for Hodgkin and non-Hodgkin lymphomas, Dr. Pro leads multi-center clinical trials evaluating new targeted therapies for patients with aggressive lymphoma subtypes, which have led to FDA approvals of novel agents.
A distinguished scholar, Dr. Pro has published more than 150 peer-reviewed research articles in highly respected journals such as the Journal of Clinical Oncology, Blood, and Lancet. Prior to joining the faculty of Columbia, Dr. Pro served as the clinical director of the lymphoma program and director of the hematology and oncology fellowship program at the Robert H. Lurie Comprehensive Cancer Center. She has received numerous awards and is a member of several organizations, including the American Society of Hematology, the American Society of Clinical Oncology, and the American Association of Cancer Research. She serves as a member of the Scientific Advisory Board for the Lymphoma Research Foundation and Scientific Committee of the Society of Hematology-Oncology.
Dr. Pro received her medical degree from the University or Rome in Italy, and completed her residency at The Mount Sinai School of Medicine in New York. She pursued her fellowship at MD Anderson Cancer Center, where she began her lymphoma research under Dr. Fernando Cabanillas.
|Lymphoma||Study of CPO107 in Patients with Non-Hodgkin's Lymphoma (NHL)|